Department of Hematology, Mater University Hospital, Dublin, Ireland.
Department of Hematology, Rotunda Hospital, Dublin, Ireland.
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):201-212. doi: 10.1182/hematology.2020002268.
Recurrent venous thromboembolism (VTE, or deep vein thrombosis and pulmonary embolism) is associated with mortality and long-term morbidity. The circumstances in which an index VTE event occurred are crucial when personalized VTE recurrence risk is assessed. Patients who experience a VTE event in the setting of a transient major risk factor (such as surgery associated with general anesthesia for >30 minutes) are predicted to have a low VTE recurrence risk following discontinuation of anticoagulation, and limited-duration anticoagulation is generally recommended. In contrast, those patients whose VTE event occurred in the absence of risk factors or who have persistent risk factors have a higher VTE recurrence risk. Here, we review the literature surrounding VTE recurrence risk in a range of clinical conditions. We describe gender-specific risks, including VTE recurrence risk following hormone- and pregnancy-associated VTE events. Finally, we discuss how the competing impacts of VTE recurrence and bleeding have shaped international guideline recommendations.
复发性静脉血栓栓塞症(VTE,即深静脉血栓形成和肺栓塞)与死亡率和长期发病率相关。在评估个体化 VTE 复发风险时,发生首发 VTE 事件的情况至关重要。在短暂的主要危险因素(如全麻相关手术>30 分钟)下发生 VTE 事件的患者,在停止抗凝治疗后预计 VTE 复发风险较低,一般建议采用有限疗程的抗凝治疗。相比之下,那些首发 VTE 事件无危险因素或存在持续性危险因素的患者 VTE 复发风险较高。在这里,我们将回顾一系列临床情况下 VTE 复发风险的相关文献。我们描述了性别特异性风险,包括与激素和妊娠相关 VTE 事件后 VTE 复发风险。最后,我们讨论了 VTE 复发和出血的竞争影响如何塑造了国际指南建议。